Boston Scientific Watchman wins FDA expansion for post-ablation patients
July 21, 2025
Boston Scientific (NYSE: BSX)+
has received expanded FDA approval for the use of its Watchman FLX and Watchman FLX Pro devices.
Boston Scientific (NYSE: BSX)+
has received expanded FDA approval for the use of its Watchman FLX and Watchman FLX Pro devices.
NDA for TAR-200 targets high-risk non-muscle invasive bladder cancer, highlighting potential to transform treatment for patients unresponsive to BCG therapy
Tiny fat bubbles carrying gene therapy have successfully repaired DNA in the lungs and liver of animals with alpha-1 antitrypsin deficiency—a promising leap toward treating humans with this rare inherited disease.
An experimental mRNA vaccine boosted the tumor-fighting effects of immunotherapy in a mouse-model study, bringing researchers one step closer to their goal of developing a universal vaccine to “wake up” the immune system against cancer.
Neurofibromatosis type 1 (NF1) is a rare genetic condition that affects approximately 100,000 Americans. Children diagnosed with the disorder often have motor delays and learning disabilities. Many are also diagnosed with autism or brain tumors.
Researchers from Aarhus University—in a major international collaboration—have developed a groundbreaking method that can provide more information from the tissue samples doctors take from patients every day.
Pioneering Study Aims to Validate Convenient, Early Detection Method for Type 1 Diabetes Outside Clinical Settings
Next-Generation Oscillating System Enhances Precision and Protects Delicate Tissue in Spine and Cranial Procedures
Certification Advances Global Access to Comprehensive Genetic Testing and Precision Medicine Solutions in Europe
UroMems announced that it received FDA investigational device exemption (IDE) approval to begin a first-of-its-kind trial for its smart implant.